Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

d(CH2)5-Davp (2S)-1- [[(10S,13S,16S,19S,22S)-16- (2...

Synonyms: d(CH2)5AVP, AC1L3X87

Rascher, W. et al., Manning, M. et al., Szczepanska-Sadowska, E. et al., Rohmeiss, P. et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Psychiatry related information on d(CH2)5AVP

In rats with sinoaortic deafferentation (SAD) 4 wk before water deprivation, d(CH2)5AVP caused a reduction of total peripheral resistance and of mean arterial pressure, whereas cardiac output remained unchanged [1].

High impact information on d(CH2)5AVP

The parent V1 antagonists are (4) [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid)] arginine-vasopressin (d(CH2)5AVP), (5) d(CH2)5VDAVP, (6) [1-deaminopenicillamine,4-valine,8-D-arginine]vasopressin (dPVDAVP), and (7) d(CH2)5[Tyr(Me)]AVP [2].
Administration of d(CH2)5AVP at a rate of 2.0 micrograms.min-1 was associated with a significant suppression of the postloading water intake and osmotic load excretion and with a delay in restitution of plasma osmolality [3].
Central (i.c.v.) pretreatment with d(CH2)5AVP, a V1-AVP receptor antagonist, completely abolished the responses to i.c.v. but not to i.v. AVP [4].
Intravenous injection of 5 micrograms/kg d(CH2)5AVP reduced total peripheral resistance [1].

References

Hemodynamic effects of arginine vasopressin in conscious water-deprived rats. Rascher, W., Meffle, H., Gross, F. Am. J. Physiol. (1985) [Pubmed]
C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors. Manning, M., Misicka, A., Olma, A., Klis, W.A., Bankowski, K., Nawrocka, E., Kruszynski, M., Kolodziejczyk, A., Cheng, L.L., Seto, J. J. Med. Chem. (1987) [Pubmed]
Thirst impairment elicited by intraventricular administration of vasopressin antagonists. Szczepanska-Sadowska, E., Sobocinska, J., Kozłowski, S. Peptides (1987) [Pubmed]
Vasopressin: mechanism of central cardiovascular action in conscious rats. Rohmeiss, P., Becker, H., Dietrich, R., Luft, F., Unger, T. J. Cardiovasc. Pharmacol. (1986) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

Editor

Share